SCHEMBL3249067

SCHEMBL3249067

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(/C=C/C(=O)NCc4ccccc4)cc3c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.49
MMP1 P03956 4/20 0.44
MMP2 P08253 4/20 0.44
MMP9 P14780 4/20 0.44
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRB2 P47870 1/20 0.43
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 3/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
LMNA P02545 1/20 0.42
HTR1A P08908 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
PMP22 Q01453 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249071 1.00 ALOX15 (0.49) ALOX15MMP1MMP2MMP9GABRA1
SCHEMBL3250568 0.89 MMP1 (0.49) MMP1MMP2MMP9KDM4EALDH1A1
SCHEMBL3250563 0.89 MMP1 (0.49) MMP1MMP2MMP9KDM4EALDH1A1
SCHEMBL3254619 0.87 ALOX15 (0.44) ALOX15MMP1MMP2MMP9KDM4E
SCHEMBL14623782 0.87 MMP1 (0.49) ALOX15MMP1MMP2MMP9KDM4E
SCHEMBL3255440 0.86 GABRA1 (0.45) GABRA1GABRB1GABRA3GABRB2KDM4E
SCHEMBL3255436 0.86 GABRA1 (0.45) GABRA1GABRB1GABRA3GABRB2KDM4E
SCHEMBL3253944 0.85 SMN1; SMN2 (0.38) ALOX15GABRA1GABRB1GABRA3GABRB2
SCHEMBL3253941 0.85 SMN1; SMN2 (0.38) ALOX15GABRA1GABRB1GABRA3GABRB2
SCHEMBL3250274 0.84 TTR (0.45) GABRA1GABRB1GABRA3GABRB2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 ALOX15 3062/4885MMP1 3251/4885MMP2 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.